Federal law restricts this drug to use by or on
the order of a licensed veterinarian.
To order, veterinarians may call Elanco at
or contact their preferred distributor.
Indications and Usage
Adequan Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.
Important Safety Information
Adequan® Canine (polysulfated glycosaminoglycan or PSGAG) should not be used in dogs who are hypersensitive to PSGAG or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Side effects in clinical studies (pain at injection site, diarrhea and abnormal bleeding) were mild, transient and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated.
©2016 Eli Lilly and Company, its subsidiaries or affiliates. USCACADE00009(1)
Elanco and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Adequan® and the Dog Head Design are registered trademarks of Luitpold Pharmaceuticals, Inc., used under license.